CA3142076C - Utilisation d'un agoniste de rxr dans le traitement de cancers her2 + - Google Patents

Utilisation d'un agoniste de rxr dans le traitement de cancers her2 +

Info

Publication number
CA3142076C
CA3142076C CA3142076A CA3142076A CA3142076C CA 3142076 C CA3142076 C CA 3142076C CA 3142076 A CA3142076 A CA 3142076A CA 3142076 A CA3142076 A CA 3142076A CA 3142076 C CA3142076 C CA 3142076C
Authority
CA
Canada
Prior art keywords
her2
therapeutic agent
rxr agonist
targeted therapeutic
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA3142076A
Other languages
English (en)
Other versions
CA3142076A1 (fr
Inventor
Powel H. Brown
Martin E. Sanders
Original Assignee
University of Texas System
IO Therapeutics Inc
Filing date
Publication date
Application filed by University of Texas System, IO Therapeutics Inc filed Critical University of Texas System
Priority claimed from PCT/US2019/036594 external-priority patent/WO2020251556A1/fr
Publication of CA3142076A1 publication Critical patent/CA3142076A1/fr
Application granted granted Critical
Publication of CA3142076C publication Critical patent/CA3142076C/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Abstract

La présente invention concerne des combinaisons d'agents actifs pour le traitement amélioré de cancers Her2 + et des procédés de traitement associés. Les combinaisons comprennent un agoniste de RXR et un agent thérapeutique ciblant Her2 et peuvent éventuellement comprendre en outre une hormone thyroïdienne.
CA3142076A 2019-06-11 Utilisation d'un agoniste de rxr dans le traitement de cancers her2 + Active CA3142076C (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2019/036594 WO2020251556A1 (fr) 2019-06-11 2019-06-11 Utilisation d'un agoniste de rxr dans le traitement de cancers her2 +

Publications (2)

Publication Number Publication Date
CA3142076A1 CA3142076A1 (fr) 2020-12-17
CA3142076C true CA3142076C (fr) 2025-07-22

Family

ID=

Similar Documents

Publication Publication Date Title
US11224583B2 (en) Use of an RXR agonist in treating HER2+ cancers
US11648223B2 (en) Receptor subtype and function selective retinoid and rexinoid compounds in combination with immune modulators for cancer immunotherapy
IL228741A (en) Use of EGFR antibody and tyrosine kinase inhibitor to make cancer treatment
KR102088469B1 (ko) Mek 억제제 및 igf1r 억제제의 병용 요법
Bastholt et al. Phase I/II clinical and pharmacokinetic study evaluating a fully human monoclonal antibody against EGFr (HuMax-EGFr) in patients with advanced squamous cell carcinoma of the head and neck
AU2019450366B2 (en) Use of an RXR agonist in treating Her2+ cancers
CA3142076C (fr) Utilisation d'un agoniste de rxr dans le traitement de cancers her2 +
US11998521B2 (en) Use of an RXR agonist in treating drug resistant HER2+ cancers
US20230172872A1 (en) Use of an rxr agonist and taxanes in treating her2+ cancers
WO2026030729A1 (fr) Utilisation d'un agoniste de rxr dans le traitement du cancer
CA3032011A1 (fr) Combinaison d'inhibiteurs du proteasome et d'anticorps anti-cd30